"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 8 | 3 | 11 |
| 1994 | 10 | 2 | 12 |
| 1995 | 9 | 1 | 10 |
| 1996 | 22 | 14 | 36 |
| 1997 | 25 | 15 | 40 |
| 1998 | 36 | 12 | 48 |
| 1999 | 29 | 18 | 47 |
| 2000 | 14 | 12 | 26 |
| 2001 | 19 | 13 | 32 |
| 2002 | 9 | 5 | 14 |
| 2003 | 18 | 8 | 26 |
| 2004 | 13 | 15 | 28 |
| 2005 | 14 | 10 | 24 |
| 2006 | 20 | 13 | 33 |
| 2007 | 8 | 13 | 21 |
| 2008 | 8 | 12 | 20 |
| 2009 | 11 | 11 | 22 |
| 2010 | 15 | 12 | 27 |
| 2011 | 13 | 8 | 21 |
| 2012 | 13 | 9 | 22 |
| 2013 | 18 | 16 | 34 |
| 2014 | 18 | 9 | 27 |
| 2015 | 4 | 12 | 16 |
| 2016 | 13 | 8 | 21 |
| 2017 | 10 | 7 | 17 |
| 2018 | 8 | 5 | 13 |
| 2019 | 8 | 11 | 19 |
| 2020 | 6 | 10 | 16 |
| 2021 | 6 | 6 | 12 |
| 2022 | 0 | 5 | 5 |
| 2023 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Immunosuppressive effects of new thiophene-based KV1.3 inhibitors. Eur J Med Chem. 2023 Nov 05; 259:115561.
-
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. Mult Scler Relat Disord. 2023 Jun; 74:104718.
-
Immunosuppression in Uterus Transplantation: Experience From the Dallas Uterus Transplant Study. Transplantation. 2023 03 01; 107(3):729-736.
-
Asymmetric Total Synthesis of (+)-Phainanoid A and Biological Evaluation of the Natural Product and Its Synthetic Analogues. J Am Chem Soc. 2023 03 01; 145(8):4828-4852.
-
Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023 01; 10(1).
-
Impact of Steroid Only Induction on Rejection in Simultaneous Liver-Kidney Transplantation. Prog Transplant. 2022 Dec; 32(4):363-369.
-
Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and International Society for Heart and Lung Transplantation: An executive summary. Pharmacotherapy. 2022 08; 42(8):594-598.
-
Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation. Pharmacotherapy. 2022 08; 42(8):599-633.
-
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors. Eur J Intern Med. 2022 09; 103:95-99.
-
Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease. J Manag Care Spec Pharm. 2022 Aug; 28(8):892-902.